Andy Tsun (Co-founder, CSO)

Andy is responsible for Discovery Biology at Biotheus. He obtained his D. Phil. (Ph. D.) from the University of Oxford, and worked as a Postdocotoral Research Scientist/Associate Professor at Institut Pasteur of Shanghai before moving into industry. Andy was previously the Director of Functional Biology at Innovent Biologics, where he was responsible for target selection and lead molecule selection/characterization. During this period, he participated and led the discovery and development of sintilimab until IND filing. Andy also led the discovery and development of multiple therapeutic antibodies to other targets such as OX40, CD47, and LAG-3.

所属分类

Back To List

产品描述

[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[[产品参数, 参数]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]

Andy is responsible for Discovery Biology at Biotheus. He obtained his D. Phil. (Ph. D.) from the University of Oxford, and worked as a Postdocotoral Research Scientist/Associate Professor at Institut Pasteur of Shanghai before moving into industry. Andy was previously the Director of Functional Biology at Innovent Biologics, where he was responsible for target selection and lead molecule selection/characterization. During this period, he participated and led the discovery and development of sintilimab until IND filing. Andy also led the discovery and development of multiple therapeutic antibodies to other targets such as OX40, CD47, and LAG-3.

关键词:

the

of

as

research

drug

and

project

chinese

new

扫二维码用手机看

Last

Jun Bao (CBO)